Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502082 · ClinicalTrials.gov registry record · Phase 1
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
A Phase 1 study, sponsored by Eureka Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04502082 is a Phase 1 study that was terminated before completion, run by Eureka Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT04502082, a Phase 1 study, was terminated before completion, sponsored by Eureka Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).
Interventions
- BIOLOGICAL ET140203 autologous T cell product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502082
The ClinicalTrials.gov registry entry for NCT04502082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eureka Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ET140203 autologous T cell product is the first listed.
NCT04502082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502082 about?
NCT04502082 is a clinical study titled "Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)". Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).
What is the current status of trial NCT04502082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-04-14. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04502082?
The interventions under investigation include: ET140203 autologous T cell product (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502082?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.